UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K-A
Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the fiscal year ended December 31, 1995
Commission File Number 0-11997
Carrington Laboratories, Inc.
(Exact name of Registrant as specified in its charter)
Texas 75-1435663
(State of Incorporation) (IRS Employer ID No.)
2001 Walnut Hill Lane, Irving, Texas 75038
(Address of principal executive offices)
Registrant's telephone number, including area code: (214) 518-1300
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of exchange on which registered
------------------- ------------------------------------
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock ($.01 par value)
(Title of class)
Preferred Share Purchase Rights
(Title of class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
<PAGE>
The aggregate market value of the voting stock held by non-affiliates of the
Registrant on March 15, 1996, was $231,721,284. (This figure was computed on
the basis of the closing price of such stock on the NASDAQ National Market on
March 15, 1996 using the aggregate number of shares held on that date by, or
in nominee name for, shareholders who are not officers, directors or record
holders of 10% or more of the Registrant's outstanding voting stock. The
characterization of such officers, directors and 10% shareholders as affiliates
is for purposes of this computation only and should not be construed as an
admission for any other purpose that any of such persons are, in fact,
affiliates of the Registrant.)
Indicate the number of shares outstanding of each of the Registrant's classes
of Common Stock, as of the latest practicable date:
8,657,421 shares of Common Stock, par value $.01 per share, were outstanding
on March 15, 1996.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's proxy statement for its annual meeting of
shareholders to be held on May 23, 1996 are incorporated by reference into
Part III hereof, to the extent indicated herein.
<PAGE>
STATEMENT
This amendment is filed soley for the purpose of Amending that portion of the
facing page that describes the securities registered persuant to Sections
12(b) and 12(g) of the Act.
SIGNITURES
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized.
CARRINGTON LABORATORIES, INC.
Date: October 4, 1996 By: /s/ Sheri L. Pantermuehl
--------------------------
Sheri L. Pantermuehl, CFO
